γδ T cells offer several advantages for solid tumor immunotherapy, including innate tumor recognition, human leukocyte antigen-independent killing, and a reduced risk of graft-versus-host disease. Their low prevalence in peripheral blood, however, makes expansion a central barrier to producing clinically relevant cell numbers.
This resource reports two distinct activation workflows for generating billions of γδ T cells from peripheral blood mononuclear cells (PBMCs). It outlines how each approach was configured and presents data on cell growth, phenotype, and functional activity relevant to γδ T cell therapy development.
Download this resource to
- Compare two activation strategies for expanding PBMC-derived γδ T cells
- Review how workflow design affects γδ T cell expansion and subset composition
- Examine functional characterization data relevant to γδ T cell therapy development
